salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
September 28, 2021 07:01 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference
September 27, 2021 08:03 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
September 20, 2021 07:33 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
August 12, 2021 14:00 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
salarius-logo-rgb-72dpi.jpg
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
July 29, 2021 07:33 ET | Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Sarcoma Foundation o
Sarcoma Foundation of America Announces 2020 Research Grant Awards
May 28, 2020 11:57 ET | Sarcoma Foundation of America
Damascus, MD, May 28, 2020 (GLOBE NEWSWIRE) -- The Sarcoma Foundation of America (SFA), an organization dedicated to increasing research and awareness for sarcoma, today announced that it has...
Sarcoma Foundation o
Sarcoma Foundation of America Announces Brandi Felser as Executive Director
February 03, 2020 08:53 ET | Sarcoma Foundation of America
Damascus, MD, Feb. 03, 2020 (GLOBE NEWSWIRE) -- The Sarcoma Foundation of America (SFA), an organization dedicated to increased research, awareness and advocacy for sarcoma, announces Brandi Felser...
Adaptimmune logo Colour_white background_no strap.jpg
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO
September 30, 2019 08:45 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented updated...
TLC_Tagline EN.png
TLC to Present Preclinical Data on TLC178 at ESMO 2019
September 23, 2019 05:00 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS
July 25, 2019 08:00 ET | Adaptimmune Therapeutics plc
- Compelling data reported with ADP-A2M4 SPEAR T-cells in synovial sarcoma - - Adaptimmune plans to launch a TCR T-cell therapy in 2022 - PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019...